JP Morgan analyst Brian Ossenbeck downgrades Norfolk Southern (NYSE:NSC) from Overweight to Neutral.
Amgen To Present New Clinical And Real-world Data Across Inflammation Portfolio At EADV September 7-10 2022
New Positive Data From Phase 3 SPROUT Trial, Studying Otezla (apremilast) in Children Ages 6-17 With Moderate to Severe Plaque Psoriasis
Positive Results From the Phase 3 DISCREET Study, Investigating Clinical Efficacy
